See more : White Organic Agro Limited (WHITEORG.BO) Income Statement Analysis – Financial Results
Complete financial analysis of NRx Pharmaceuticals, Inc. (NRXP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NRx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Diales Plc (DIAL.L) Income Statement Analysis – Financial Results
- China Regenerative Medicine International Limited (8158.HK) Income Statement Analysis – Financial Results
- AXP Energy Limited (AXP.AX) Income Statement Analysis – Financial Results
- Suzhou Sunmun Technology Co., Ltd. (300522.SZ) Income Statement Analysis – Financial Results
- Mauna Kea Technologies SA (MKEA.PA) Income Statement Analysis – Financial Results
NRx Pharmaceuticals, Inc. (NRXP)
About NRx Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 5.00K | 4.00K | 2.00K | 907.41K | 0.00 | 1.01M | 0.00 |
Gross Profit | -5.00K | -4.00K | -2.00K | -907.41K | 0.00 | -1.01M | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 13.37M | 17.03M | 20.26M | 10.63M | 3.50K | 0.00 | 0.00 |
General & Administrative | 14.22M | 27.37M | 74.94M | 11.44M | 2.77K | 0.00 | 0.00 |
Selling & Marketing | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 14.21M | 27.37M | 74.94M | 11.44M | 2.77K | 1.01M | 0.00 |
Other Expenses | 0.00 | -505.00K | -771.00K | -10.16M | 713.19K | 1.01M | 0.00 |
Operating Expenses | 27.58M | 44.40M | 94.43M | 11.90M | 6.43K | 1.01M | 0.00 |
Cost & Expenses | 27.59M | 44.40M | 94.43M | 11.90M | 6.43K | 1.01M | 0.00 |
Interest Income | 494.00K | 249.00K | 18.00 | 56.00 | 1.21M | 1.09M | 0.00 |
Interest Expense | 120.00K | 0.00 | 18.00K | 56.00K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 5.00K | 4.00K | 2.00K | 2.00K | 0.86 | 1.09M | 52.52K |
EBITDA | -30.03M | -39.75M | -93.04M | -51.72M | -713.19K | 82.41K | -105.04K |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -27.59M | -44.40M | -115.80M | -51.39M | -6.26K | -1.01M | 0.00 |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -2.57M | 4.58M | 22.73M | -39.88M | 1.21M | 1.09M | -105.03K |
Income Before Tax | -30.16M | -39.82M | -93.06M | -51.78M | 492.63K | 82.41K | -105.03K |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | -9.00K | -4.58M | -21.35M | -39.43M | 84.21K | 16.31K | 0.00 |
Net Income | -30.15M | -35.24M | -71.72M | -12.35M | 408.43K | 66.10K | -105.03K |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
EPS Diluted | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
Weighted Avg Shares Out | 7.58M | 65.77M | 46.92M | 34.27M | 508.84K | 892.50K | 903.55K |
Weighted Avg Shares Out (Dil) | 7.58M | 65.77M | 46.92M | 34.27M | 508.84K | 892.50K | 903.55K |
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds
Source: https://incomestatements.info
Category: Stock Reports